Differential diagnosis and appropriate treatment of four thyrotoxic patients with graves' disease required to take amiodarone due to life-threatening arrhythmia

Internal Medicine

Volumn 47, Issue 8, 2008, Pages 757-762

  Sato, Kanji ^a   Omi, Yoko ^a   Kodama, Hitomi ^a   Obara, Takao ^a   Yamazaki, Kazuko ^b   Yamada, Emiko ^b   Seki, Toshiro ^a   Takano, Kazue ^a   Shiga, Tsuyoshi ^a   Kasanuki, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Kanaji Hospital   (Japan)

Author keywords

Amiodarone; Thyroidectomy; Thyrotoxicosis

Indexed keywords

AMIODARONE; BISOPROLOL FUMARATE; CARVEDILOL; FUROSEMIDE; IODINE; LAXATIVE; LEVOTHYROXINE; LOSARTAN; LUGOL; POTASSIUM CHLORIDE; PREDNISOLONE; PROPYLTHIOURACIL; SPIRONOLACTONE; THIAMAZOLE; WARFARIN; ANTIARRHYTHMIC AGENT; ANTITHYROID AGENT;

ADULT; ARTICLE; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; DEFIBRILLATOR; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAVES DISEASE; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; MALE; SUBTOTAL THYROIDECTOMY; THROMBOCYTOPENIA; THYROIDECTOMY; THYROTOXICOSIS; TREATMENT INDICATION; TREATMENT PLANNING; MIDDLE AGED;

ADULT; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTITHYROID AGENTS; ARRHYTHMIAS, CARDIAC; DIAGNOSIS, DIFFERENTIAL; GRAVES DISEASE; HUMANS; MALE; METHIMAZOLE; MIDDLE AGED; THYROIDECTOMY; THYROTOXICOSIS;

EID: 44649159193     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0843     Document Type: Article

References (30)

1. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 22: 240-254, 2001.
2. Basaria S, Cooper DS. Amiodarone and thyroid. Am J Med 116: 706-714, 2005.
3. Klein I, Danzi S. Thyroid disease and the heart. Circulation 116: 1725-1735, 2007.
4. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab 81: 2930-2933, 1996.
5. Bogazzi F, Martino E, Dell'Unto E, et al. Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest 26: 635-640, 2003.
6. Loy M, Perra E, Melis A, et al. Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Acta Radiol 48: 628-634, 2007.
7. Sato K, Miyakawa M, Eto M, et al, Clinical characteristics of amiodarone-induced thyrotoxicosis and hypothyroidism in Japan. Endocrine J 46: 443-451, 1999.
8. 123I uptake (2 cases). Folia Endocnrinol Jpn 82: 315, 2006 (abstract).
9. Sato K, Shiga T, Kasanuki H. Amiodarone and Thyroid Dysfunction. In: Arrhythmia 2007. Sugimoto K, Inoue H, Eds. Medical View, 2007: 189-197 (in Japanese).
10. Yamazaki K, Mitsuhashi M, Yamada E, et al. Amiodarone reversibly decreases sodium-iodide symporter mRNA expression at therapeutic concentrations and induces antioxidant responses at supraphysiological concentrations in cultured human thyroid follicles. Thyroid 17: 1189-1200, 2007.
11. Sato K, Yamazaki K, Kanaji Y, Ohnishi S, Kasanuki H, Demura H. Amiodarone-induced thyrotoxicosis associated with thyrotropin receptor antibody. Thyroid 8: 1123-1126, 1998.
12. Daniels GH. Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 86: 3-8, 2001.
13. Martino E, Bartalena L, Mariotti S, et al. Radioactive iodine uptake in patients with amiodarone iodine-induced thyroid dysfunction. Acta Endocrinol (Copenh) 119: 167-173, 1988.
14. Ryan LE, Braverman LE, Cooper DS, Ladenson PW, Kloos RT. Can amiodarone be restarted after amiodarone-induced thyrotoxicosis? Thyroid 14: 149-153, 2000.
15. Bartalena L, Wiersinga WM, Tanda ML, et al. Diagnosis and management of arniodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clin Endocrinol (Oxf) 61: 494-502, 2004.
16. Diehl LA, Romaldini JH, Graf H, Bartalena L, Martino E, Albino CC, Wiersinga WM. Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey. Clin Endocrinol (Oxf) 65: 433-438, 2006.
17. Shiga T, Wakaumi M, Matsuda N, et al. Amiodarone-induced thyroid dysfunction and ventricular tachyarrhythmia during long-term therapy in Japan. Jpn Circulation J 65: 958-960, 2001.
18. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 92: 2157-2162, 2007.
19. Bogazzi F, Bartalena L, Brogioni S, et al. Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid 7: 541-545, 1997.
20. Sato K, Shiga T, Matsuda N, et al. Mild and short recurrence of type II amiodarone-induced thyrotoxicosis in three patients receiving amiodarone continuously for more than 10 years. Endocr J 53: 531-538, 2006.
21. Jeng CY, Bian TY, Shian LR, Huang HW, Shen DD, Liu PH. A comparative study of the short therapeutic effect of amiodarone and iodine on Graves' thyrotoxicosis. Taiwan Yi Xue Hui Za Zhi 83: 1238-1246, 1984.
22. Sato K, Yamazaki K, Shizume K, et al. Stimulation by thyroid stimulating hormone and Graves' immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 96: 1295-1302, 1995.
23. Yamada E, Yamazaki K, Takano K, Obara T, Sato K. Iodide inhibits vascular endothelial growth factor (VEGF)-A expression in cultured human thyroid follicles: a microarray search for effects of TSH and iodide on angiogenesis factors. Thyroid 16: 545-554, 2006.
24. Brownlie BEW, Turner JG, Ellwood MA, Rogers TGH, Armstrong DI. Thyroid vascularity-documentation of the iodide effect in thyrotoxicosis. Acta Endocrinol 86: 317-322, 1977.
25. Hamoir E, Meurisse M, Defechereux T, Joris J, Vivario J, Hennen G. Surgical management of amiodarone-associated thyrotoxicosis: too risky or too effective? World J Surg 22 (6): 537-543, 1998.
26. Houghton SG, Farley DR, Brennan MD, van Heerden JA, Thompson GB, Grant CS. Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. World J Surg 28 (11): 1083-1087, 2004.
27. Gough J, Gough IR. Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease. Word J Surg 30: 1957-1961, 2006.
28. Check JH, Avelino J. Painless thyroiditis and transient thyrotoxicosis after Graves' disease. JAMA 244: 1361, 1980.
29. Izumi Y, Takeoka K, Amino N. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease. Endocr J 52: 493-497, 2005.
30. Wiersinga WM, Touber JL, Trip MD, van Royen EA. Uninhibited thyroidal uptake of radioiodine despite iodine excess in amiodarone-induced hypothyroidism. J Clin Endocrinol Metab 63: 485-491, 1986.